HistoSonics hits enrollment target en route to FDA filing for liver cancer therapy
The company reports it has met the enrollment target for a trial of its sonic beam therapy, one step closer to submitting for FDA approval of the product.
The company reports it has met the enrollment target for a trial of its sonic beam therapy, one step closer to submitting for FDA approval of the product.
DIA 2022
The company has introduced a mobile application designed to streamline and automate training in a single platform for sponsors, CROs, and research sites.